CervoMed Inc. Net Income (Loss) Available to Common Stockholders, Diluted
CervoMed Inc. (CRVO) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$4.75 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2024-11-12
- CervoMed Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2024-09-30 was -$4.75M.
- CervoMed Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2023-09-30 was -$2.63M.
- CervoMed Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2022-09-30 was -$882.62K.
- CervoMed Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2018-12-31 was -$5.57M.
- CervoMed Inc. net income (loss) available to common stockholders, diluted for fiscal 2018 was -$26.62M.
- CervoMed Inc. net income (loss) available to common stockholders, diluted for fiscal 2017 was -$24.69M.
- CervoMed Inc. net income (loss) available to common stockholders, diluted for fiscal 2016 was -$18.04M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$4.75M 10-Q · filed 2024-11-12 | -$9.58M 10-Q · filed 2024-11-12 | ||
| 2023-09-30 | -$2.63M 10-Q · filed 2024-11-12 | -$5.23M 10-Q · filed 2024-11-12 | ||
| 2022-09-30 | -$882.62K 10-Q · filed 2023-11-13 | -$4.28M 10-Q · filed 2023-11-13 | ||
| 2018-12-31 | -$5.57M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-19 | -$12.29M derived: sum of 2 quarters · filed 2019-03-19 | -$15.06M derived: sum of 3 quarters · filed 2019-03-19 | -$26.62M 10-K · filed 2019-03-19 |
| 2018-09-30 | -$6.72M 10-Q · filed 2018-11-13 | -$9.48M derived: sum of 2 quarters · filed 2018-11-13 | -$21.05M 10-Q · filed 2018-11-13 | -$22.77M derived: sum of 4 quarters · filed 2019-03-19 |
| 2018-06-30 | -$2.77M 10-Q · filed 2018-08-10 | -$14.33M 10-Q · filed 2018-08-10 | -$16.05M derived: sum of 3 quarters · filed 2019-03-19 | -$13.12M derived: sum of 4 quarters · filed 2019-03-19 |
| 2018-03-31 | -$11.57M derived: 10-K 12 month − 3 quarters · filed 2019-03-19 | -$13.28M derived: sum of 2 quarters · filed 2019-03-19 | -$10.36M derived: sum of 3 quarters · filed 2019-03-19 | -$24.26M derived: sum of 4 quarters · filed 2019-03-19 |
| 2017-12-31 | -$1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-19 | $1.21M derived: sum of 2 quarters · filed 2019-03-19 | -$12.70M derived: sum of 3 quarters · filed 2019-03-19 | -$24.69M 10-K · filed 2019-03-19 |
| 2017-09-30 | $2.92M 10-Q · filed 2018-11-13 | -$10.98M derived: sum of 2 quarters · filed 2018-11-13 | -$22.98M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | -$13.90M 10-Q · filed 2018-08-10 | -$19.27M 10-Q · filed 2018-08-10 | ||
| 2016-12-31 | -$2.57M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | -$8.01M derived: sum of 2 quarters · filed 2018-04-02 | -$11.81M derived: sum of 3 quarters · filed 2018-04-02 | -$18.04M 10-K · filed 2018-04-02 |
| 2016-09-30 | -$5.44M 10-Q · filed 2017-11-13 | -$9.24M derived: sum of 2 quarters · filed 2017-11-13 | -$15.47M 10-Q · filed 2017-11-13 | |
| 2016-06-30 | -$3.81M 10-Q · filed 2017-08-14 | -$10.03M 10-Q · filed 2017-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |